HSP90AB1 and lung adenocarcinoma: However, as not all lung adenocarcinomas respond equally to HSP90 inhibitors [32,33], a better understanding of the cellular consequences of HSP90 inhibition will therefore be key to improve clinical outcomes in this tumor type.